Iron overdose: A contributor to adverse outcomes in randomized trials of anemia correction in CKD

International Urology and Nephrology

Volumn 44, Issue 2, 2012, Pages 499-507

  Van Buren, Peter ^a   Velez, Ruben L ^b   Vaziri, Nosratola D ^c,d   Zhou, Xin J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Nephrology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Chronic kidney disease; End stage renal disease; Hemodialysis; Iron

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG METABOLISM; ENDOTHELIAL DYSFUNCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; IRON OVERLOAD; KIDNEY FAILURE; KIDNEY INJURY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PREVALENCE; RETICULOENDOTHELIAL SYSTEM; RETROSPECTIVE STUDY;

ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRON; IRON COMPOUNDS; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK FACTORS; WORLD HEALTH;

EID: 84863108673     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0028-5     Document Type: Article

References (67)

1. Vaziri N (2008) Anemia and anemia correction: surrogate markers or causes of mortality in chronic kidney disease. Nat Clin Pract Nephrol 8:436-445
2. Vaziri N, Zhou X (2009) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24: 1082-1088
3. Ma J, Ebben J, Xia H, Collins A (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619 (Pubitemid 29117643)
4. Collins A, Li S, Peter W et al (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 12:2465-2473 (Pubitemid 33021125)
5. Robinson B, Joffe M, Berns J, Pisoni R, Port F, Feldman H (2005) Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68:2323-2330 (Pubitemid 43117811)
6. Locatelli F, Pisoni R, Combe C et al (2004) Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 19:121-132 (Pubitemid 38072623)
7. Xia H, Ebben J, Ma J, Collins A (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316 (Pubitemid 29246997)
8. Li S, Collins A (2004) Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65:626-633 (Pubitemid 38130658)
9. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus J (2003) The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908-1914 (Pubitemid 36513341)
10. Wolfe R, Hulbert-Shearon T, Ashby V, Mahadevan S, Port F (2002) Improvements in dialysis patient mortality are associated with improvements in urea reduction ration and hematocrit, 1999-2002. Am J Kidney Dis 45:127-135 (Pubitemid 40038053)
11. NKF-K/DOQI (2006) Clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 47(Suppl 4):S1
12. Besarab A, Bolton W, Browne J et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 339:584-590 (Pubitemid 28385655)
13. Drueke T, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 355:2071-2084 (Pubitemid 44749316)
14. Singh A, Szczech L, Tang K et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 355:2085-2098 (Pubitemid 44749317)
15. NKF-K/DOQI (2007) Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:474
16. Spittle M, Hoenich N, Handelman G, Adhikarla R, Homel P, Levin N (2001) Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413 (Pubitemid 34193135)
17. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820 18. Schulz E, Gori T, Munzel T (2011) Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 34:665-673 (Pubitemid 34000785)
18. Schulz E, Gori T, Munzel T (2011) Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 34:665-673
19. Szczech L, Barnhart H, Inrig J et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798
20. Kuo C, Lee C, Chuang C, Su Y, Chen J (2005) Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis. Clin Nephrol 63:92-97 (Pubitemid 40298043)
21. Goodkin DF, Fuller DS, Robinson B et al (2011) Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 22:358-365
22. Parfrey P, Foley R, Wittreich B et al (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180-2189 (Pubitemid 41716451)
23. Goodkin D (2009) The normal hematocrit cardiac trial revisited. Semin Dial 22:495-502
24. Jacobs A (1977) Low molecular weight intracellular iron transport compounds. Blood 50:433-439 (Pubitemid 8180426)
25. Burkitt M, Mason R (1991) Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: An ESR spin-trapping investigation. Proc Natl Acad Sci USA 88:8440-8444 (Pubitemid 21915372)
26. Broedbaek K, Poulsen H, Weimann A et al (2009) Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 47:1230-1233
27. Kell D (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2:2
28. Beshara S, Lundquist H, Sundin J et al (1999) Kinetic analysis of 52 Fe-labelled iron (III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br J Hematol 104:288-295 (Pubitemid 29083336)
29. Zanen A, Adriaansen H, van Bommel E, Posthuma R, de Jong G (1996) Oversaturation of transferrin after intravenous ferric gluconate (ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11:820-824
30. Kooistra M, Kersting S, Lu G et al (2002) Nontransferrinbound iron in the plasma of the haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Investig 32(Suppl 1):36-41 (Pubitemid 41704986)
31. Henderson P, Hillman R (1969) Characteristics of iron dextran utilization in man. Blood 34:357-375
32. Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19:561-565 (Pubitemid 38263113)
33. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H (2003) Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65:1973-1978 (Pubitemid 36629581)
34. Provenzano R, Schiller B, Rao M et al (2009) Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4:386-393
35. Spinowitz B, Kausz A, Baptista J et al (2008) Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19:1599-1605
36. Johnson A, Becker K, Zager R (2010) Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Renal Phys 299:F426-F435
37. Lu M, Suh K, Lee H, Cohen M, Rieves D, Pazdur R (2010) FDA review of ferumoxytol (feraheme) for the treatment of iron deficiency anemia in adults with chronic kidney disease. Am J Hematol 85:315-319
38. US Renal Data System (2010) USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, Bethesda
39. Zager R, Johnson C, Hanson S, Wasse H (2002) Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103 (Pubitemid 34701216)
40. Rooyakers T, Stroes E, Kooistra M et al (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Investig 32(Suppl 1):9-16 (Pubitemid 41704982)
41. Roob J, Khoschsorur G, Tiran A et al (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549 (Pubitemid 30115084)
42. Garcia-Fernandez N, Echevarria A, Sanchez-Ibarrola A, Paramo J, Coma-Cannela I (2010) Randomized clinical trial on acute effects of i.v. iron sucrose during hemodialysis. Nephrology 15:178-183
43. Salahudeen A, Oliver B, Bower J, Roberts L (2001) Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525-1531 (Pubitemid 32960048)
44. Kuo K, Hung S, Wei Y, Tarng D (2008) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 19:1817-1826
45. Tovbin D, Mazour D, Voroblov M, Chalmovitz C, Meyerstein N (2002) Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005-1012 (Pubitemid 35265481)
46. Agarwal R, Vasavada N, Sachs N, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289 (Pubitemid 38670014)
47. Kielstein J, Boger R, Bode-Boger S (1999) Asymmetric dimethyl arginine concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600 (Pubitemid 29117641)
48. Zoccali C, Bode-Boger S, Mallamaci F et al (2001) Plasma concentrations of asymmetrical dimethyl arginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117 (Pubitemid 34094901)
49. Matsuguma K, Ueda S, Yamagishi S et al (2006) Molecular mechanisms for elevation of asymmetric dimethyl arginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17:2176-2183 (Pubitemid 44141907)
50. Kartikasari A, Georgiou N, Visseren F, van Kats-Renaud H, van Sweder A, Marx J (2006) Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera. FASEB J 20:353-355 (Pubitemid 46671169)
51. Schaller G, Scheibert-Mohdehkar B, Wolzt M et al (2005) Intravenous iron increases labile serum iron but does not impair blood flow reactivity in dialysis patients. Kidney Int 68:2814-2822 (Pubitemid 43251028)
52. Reis K, Guz G, Ozdemir H et al (2005) Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease. Int Heart J 46:255-264
53. Duffy S, Biegelsen E, Holbrook M et al (2001) Iron chelation improves endothelial cell function in patients with coronary artery disease. Circulation 103:2799-2804 (Pubitemid 32550067)
54. Zager R (2005) Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68:1533-1542 (Pubitemid 43173381)
55. Agarwal R (2006) Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69:1259-1263
56. Weiss G, Meusberger E, Radacher G, Garimorth K, Neyer U, Myaer G (2003) Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64:572-578 (Pubitemid 36871928)
57. Sarnak M, Jaber B (2000) Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 58:1758-1764
58. Kato S, Chmielewski M, Honda H et al (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3:1526-1533
59. Djeha A, Brock J (1992) Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biopys Acta 1133:147-152
60. Deicher R, Ziai F, Cohen G, Mullner M, Horl W (2003) High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64:728-736 (Pubitemid 36871948)
61. Guo D, Jaber B, Lee S et al (2002) Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 58:134-142 (Pubitemid 34855094)
62. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A (2010) Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 17:11-16
63. Tenopoulou M, Doulias P, Barbouti A, Brunk U, Galaris D (2005) Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem J 387:703-710 (Pubitemid 40685704)
64. Zager R, Johnson A, Hanson S (2004) Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 66:144-156 (Pubitemid 38870090)
65. Agarwal R (2005) On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol 288:F265-F271 (Pubitemid 40105384)
66. Agarwal R, Rizkala A, Kaskas M, Minasian R, Trout J (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72:638-642 (Pubitemid 47312801)
67. Leehey D, Palubiak D, Chebrolu S, Agarwal R (2005) Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 20:135-140 (Pubitemid 40207618)